疫苗板塊走弱 復星醫藥(600196.SH)跌超5%
格隆匯5月18日丨疫苗板塊多股跳水,復星醫藥跌超5%,西藏藥業跌超3%,康泰生物、康希諾、沃森生物等紛紛下行。

昨日,外交部表示發展中國家希望豁免新冠疫苗知識產權的訴求,中方完全理解並支持。
世衞組織總幹事譚德塞昨日表示,全球新冠肺炎新增病例和死亡人數已連續兩週下降。不過一些國家的局勢仍然令人擔憂,在全球各地的疫情都結束前,新冠肺炎大流行還會延續很長時間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.